AWK1 Stock Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avadel Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.30 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$8.75 |
| Beta | 1.63 |
| 1 Month Change | 25.44% |
| 3 Month Change | 6.72% |
| 1 Year Change | 59.78% |
| 3 Year Change | 108.76% |
| 5 Year Change | 1,275.00% |
| Change since IPO | 156.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWK1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.9% | 2.3% | 0.5% |
| 1Y | 59.8% | -28.6% | 1.3% |
Return vs Industry: AWK1 exceeded the German Pharmaceuticals industry which returned -30.1% over the past year.
Return vs Market: AWK1 exceeded the German Market which returned 1.4% over the past year.
Price Volatility
| AWK1 volatility | |
|---|---|
| AWK1 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AWK1 has not had significant price volatility in the past 3 months.
Volatility Over Time: AWK1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 154 | Greg Divis | www.avadel.com |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc Fundamentals Summary
| AWK1 fundamental statistics | |
|---|---|
| Market cap | €1.45b |
| Earnings (TTM) | -€150.79m |
| Revenue (TTM) | €26.31m |
51.8x
P/S Ratio-9.0x
P/E RatioIs AWK1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWK1 income statement (TTM) | |
|---|---|
| Revenue | US$27.96m |
| Cost of Revenue | US$846.00k |
| Gross Profit | US$27.12m |
| Other Expenses | US$187.39m |
| Earnings | -US$160.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 96.97% |
| Net Profit Margin | -573.17% |
| Debt/Equity Ratio | 37.3% |
How did AWK1 perform over the long term?
See historical performance and comparison